Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$17.73+1.03 (+6.17%)
Close on Nov 18, 2026Market cap $1.75BP/E –Yield –
Ultragenyx Pharmaceutical operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Ultragenyx Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was -$528.17M. For fiscal 2025 it was -$535.00M. The highest annual figure on record is -$15.99M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$535.00M | – |
| FY2024 | Dec 31, 2024 | -$536.00M | – |
| FY2023 | Dec 31, 2023 | -$569.00M | – |
| FY2022 | Dec 31, 2022 | -$648.92M | – |
| FY2021 | Dec 31, 2021 | -$381.74M | – |
| FY2020 | Dec 31, 2020 | -$330.12M | – |
| FY2019 | Dec 31, 2019 | -$424.17M | – |
| FY2018 | Dec 31, 2018 | -$371.37M | – |
| FY2017 | Dec 31, 2017 | -$328.94M | – |
| FY2016 | Dec 31, 2016 | -$248.01M | – |
| FY2015 | Dec 31, 2015 | -$147.74M | – |
| FY2014 | Dec 31, 2014 | -$56.78M | – |
| FY2013 | Dec 31, 2013 | -$32.28M | – |
| FY2012 | Dec 31, 2012 | -$15.99M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$75.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$169.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$113.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$170.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$108.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$143.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$122.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$131.99M | – |
| Q2 FY2024 | Jun 30, 2024 | -$116.36M | – |
| Q1 FY2024 | Mar 31, 2024 | -$165.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$121.84M | – |
| Q3 FY2023 | Sep 30, 2023 | -$145.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$147.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$154.11M | – |
| Q4 FY2022 | Dec 31, 2022 | -$145.63M | – |
| Q3 FY2022 | Sep 30, 2022 | -$225.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$141.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$136.63M | – |
| Q4 FY2021 | Dec 31, 2021 | -$102.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$89.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$82.78M | – |
| Q1 FY2021 | Mar 31, 2021 | -$106.57M | – |
| Q4 FY2020 | Dec 31, 2020 | -$96.08M | – |
| Q3 FY2020 | Sep 30, 2020 | -$50.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$63.06M | – |
| Q1 FY2020 | Mar 31, 2020 | -$120.67M | – |
| Q4 FY2019 | Dec 31, 2019 | -$94.45M | – |
| Q3 FY2019 | Sep 30, 2019 | -$118.03M | – |
| Q2 FY2019 | Jun 30, 2019 | -$112.47M | – |
| Q1 FY2019 | Mar 31, 2019 | -$99.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$90.34M | – |
| Q3 FY2018 | Sep 30, 2018 | -$89.65M | – |
| Q2 FY2018 | Jun 30, 2018 | -$94.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$96.49M | – |
| Q4 FY2017 | Dec 31, 2017 | -$96.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$83.71M | – |
| Q2 FY2017 | Jun 30, 2017 | -$78.44M | – |
| Q1 FY2017 | Mar 31, 2017 | -$69.95M | – |
| Q4 FY2016 | Dec 31, 2016 | -$70.55M | – |
| Q3 FY2016 | Sep 30, 2016 | -$65.78M | – |
See a number that looks wrong?